2'-FdC Antiviral Replicon Assay Substitute | High Purity
Implementing 2'-FdC as a Validated Antiviral Replicon Assay Substitute
2'-Deoxy-2'-fluorocytidine (2'-FdC) functions as a critical nucleoside analog in the evaluation of RNA virus replication inhibitors, specifically within subgenomic replicon systems. In HCV replicon assays utilizing Huh-7 cells, this compound demonstrates a 90% effective concentration (EC90) of 5.0 μM for reducing intracellular replicon RNA levels. The therapeutic index is established by a cellular toxicity concentration (CC50) exceeding 100 μM after 96 hours of incubation, yielding a selectivity ratio greater than 20. This profile distinguishes it from cytotoxic agents that compromise cell viability before achieving viral suppression.
Dynamic profiling indicates that 2'-FdC treatment induces cytostasis via S-phase arrest rather than immediate cytotoxicity. This mechanism is vital for distinguishing direct antiviral activity from general cell growth inhibition during screening. When implementing this antiviral intermediate in replicon-based systems, researchers must account for the obligatory requirement for logarithmic cell growth to maintain steady-state replicon levels. Static efficacy measurements at day 4 may not fully capture compound-related changes in cell growth rates; therefore, monitoring RNA levels and cell growth dynamics over a 7-day period is recommended to validate the substitution effect accurately.
For laboratories sourcing materials for these assays, verifying the chemical identity and purity is paramount. NINGBO INNO PHARMCHEM CO.,LTD. supplies research grade batches characterized by rigorous analytical data to ensure consistency in replicon screening outcomes. The compound's stability in culture media and its phosphorylation kinetics by cellular kinases, such as deoxycytidine kinase, directly influence the observed EC90 values.
Mechanism of Action for 2'-Deoxy-2'-fluorocytidine in RNA Virus Screening
The antiviral activity of 2'-FLUORO-D-CYTIDINE is primarily mediated through its conversion to the 5'-triphosphate metabolite (FdCTP). This metabolite acts as a competitive inhibitor of viral RNA-dependent RNA polymerases. In the context of Hepatitis C Virus (HCV), FdCTP inhibits the NS5B polymerase with a 50% inhibitory concentration (IC50) of 14.9 μM in vitro. The 2'-fluoro modification allows the molecule to mimic natural cytidine triphosphates while resisting further metabolism or incorporation that leads to chain termination in some contexts, although incorporation into cellular nucleic acids does occur.
Structural analysis confirms that the 2'-fluoro group is isosteric with a hydroxyl group, allowing the nucleoside to adopt a 3'-endo conformation typical of ribonucleosides. This conformational preference enables recognition by viral polymerases despite the deoxy sugar backbone. However, the compound also interacts with cellular targets. FdCTP serves as a substrate for human DNA polymerases α and γ, leading to incorporation into cellular DNA and RNA. This off-target activity contributes to the observed cytostatic effects, specifically the accumulation of cells in the S-phase of the cell cycle.
Understanding this dual mechanism is essential for interpreting screening data. Inhibition of viral replication may be partially attributed to the suppression of cellular functions required for viral propagation. The phosphorylation step is rate-limiting in certain cell lines; for instance, lack of deoxycytidine kinase activity can render cells resistant to the compound. Consequently, assay results must be correlated with cellular kinase expression profiles to ensure the pharmaceutical building block is being activated effectively within the specific test system.
Comparative In Vitro Potency Against H5N1 and Pandemic H1N1 Strains
Broad-spectrum evaluation of 2'-FdC reveals significant potency against influenza A viruses, including highly pathogenic avian influenza (HPAIV) H5N1 and pandemic H1N1 strains. In MDCK cell cultures, the compound inhibits virus-induced cytopathic effect (CPE) and reduces virus yield. The inhibitory concentrations vary by strain and assay method, ranging from visual inspection to neutral red uptake and virus yield reduction (VYR) assays.
Data indicates that 2'-FdC potently inhibits the A/Hong Kong/213/2003 (H5N1) virus with an IC50 of 0.05 μM in visual assays and 0.27 μM in neutral red uptake assays. The IC90 value, representing a 1-log10 drop in virus titer, is recorded at 1.54 μM. Against pandemic H1N1 strains such as A/CA/07/2009, the IC50 values are slightly higher, ranging from 3.2 μM to 4.1 μM depending on the assay modality. The selectivity index (SI) remains favorable, often exceeding 100, due to the high CC50 values observed in MDCK cells.
The following table summarizes the comparative in vitro potency parameters across key viral strains and assay types:
| Virus Strain | Assay Type | IC50 (μM) | CC50 (μM) | Selectivity Index (SI) | IC90 (μM) |
|---|---|---|---|---|---|
| H5N1 (A/Hong Kong/213/2003) | Visual CPE | 0.05 ± 0.01 | >100 | >1954 | 1.54 |
| H5N1 (A/Hong Kong/213/2003) | Neutral Red Uptake | 0.27 ± 0.14 | >100 | >447 | 1.54 |
| H5N1 (A/Vietnam/1203/2004) | Visual CPE | 8.0 ± 10.4 | >100 | >36 | 2.9 |
| H1N1 (A/CA/07/2009) | Visual CPE | 3.2 | >100 | >31 | 4.6 |
| H1N1 (A/CA/07/2009) | Neutral Red Uptake | 4.1 | >100 | >24 | 4.6 |
| HCV (Con1 Replicon) | RNA Reduction | N/A (EC90) | >100 | >20 | 5.0 (EC90) |
Comparative analysis with difluoro analogs, such as gemcitabine, shows that while adding a second fluoro group may enhance in vitro potency (IC50 <0.032 μM for some strains), it often introduces significant cytotoxicity in vivo. 2'-FdC maintains a balance between potency and tolerability, making it a preferred candidate for further development. The 2'-FdC structure allows for broad-spectrum activity against Influenza B viruses as well, with IC90 values ranging from 2.1 μM to 7.3 μM across different strains.
Correlating Replicon Screening Results with In Vivo Survival Protection
Translating in vitro replicon and cell culture data to in vivo efficacy requires careful consideration of pharmacokinetics and dosing regimens. In BALB/c mouse models infected with lethal doses of H5N1 influenza A/Vietnam/1203/2004, 2'-FdC demonstrates significant survival protection. Administration of 60 mg/kg/day intraperitoneally (i.p.), divided into twice-daily doses for 8 days, resulted in 80% survival when treatment began 24 hours post-exposure. This correlates with the compound's ability to reduce lung virus titers and ameliorate lung pathology, although virus titer reduction was less pronounced compared to reference compounds like ribavirin.
A critical finding for therapeutic windows is the efficacy of delayed treatment. Administration of 2'-FdC at 60 mg/kg/day starting 72 hours post-virus exposure still protected 60% of mice from lethal infection. This suggests a robust mechanism of action that remains effective even after significant viral replication has occurred. In pandemic H1N1 models, a dose of 30 mg/kg/day administered twice daily for 5 days enhanced survival by 50%, indicating dose-dependent efficacy across different influenza subtypes.
Toxicity profiles in vivo differ from in vitro cytostasis. While high doses (80 mg/kg/day) showed detrimental effects on weight recovery, the 60 mg/kg/day regimen was well-tolerated with minimal adverse events. Lung weight measurements, serving as a proxy for edema and inflammation, were significantly lower in treated groups compared to placebo controls. These in vivo metrics validate the synthesis route and purity standards required for preclinical candidates, as impurities could exacerbate toxicity or reduce efficacy.
Procurement Specifications for Research Grade 2'-Deoxy-2'-fluorocytidine
For R&D applications involving antiviral screening and mechanism of action studies, procurement specifications must align with the sensitivity of the biological assays. High-performance liquid chromatography (HPLC) purity should exceed 98% to minimize interference from synthetic byproducts that may exhibit independent biological activity. Gas chromatography-mass spectrometry (GC-MS) and nuclear magnetic resonance (NMR) data are essential for confirming the structural integrity of the 2'-fluoro modification and the cytidine base.
When evaluating suppliers, request batch-specific Certificates of Analysis (COA) that detail residual solvent levels, heavy metal content, and water content. Consistency in industrial purity is crucial for longitudinal studies where batch-to-batch variation could skew IC50 or EC90 calculations. NINGBO INNO PHARMCHEM CO.,LTD. adheres to strict quality control protocols to ensure that each lot of 2'-Deoxy-2'-fluorocytidine nucleoside analog meets the rigorous demands of pharmaceutical research. Storage conditions typically require protection from moisture and light to prevent hydrolysis or degradation of the glycosidic bond.
Global supply chains for specialized nucleosides require verification of manufacturing processes to ensure scalability without compromising quality. Specifications should include detailed information on the counter-ion if supplied as a salt, as well as the specific polymorphic form if applicable. For large-scale synthesis or screening campaigns, securing bulk pricing quotes based on verified purity specs ensures cost-effective progression from hit-to-lead optimization.
To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.